Oppenheimer Asset Management Inc. Grows Stake in United Therapeutics Corporation $UTHR

Oppenheimer Asset Management Inc. grew its stake in shares of United Therapeutics Corporation (NASDAQ:UTHR) by 10.8% during the third quarter, HoldingsChannel reports. The firm owned 18,510 shares of the biotechnology company’s stock after buying an additional 1,806 shares during the period. Oppenheimer Asset Management Inc.’s holdings in United Therapeutics were worth $7,760,000 as of its most recent SEC filing.

A number of other large investors have also modified their holdings of the stock. CWM LLC increased its stake in shares of United Therapeutics by 204.3% in the second quarter. CWM LLC now owns 5,194 shares of the biotechnology company’s stock worth $1,492,000 after buying an additional 3,487 shares during the last quarter. AXQ Capital LP grew its holdings in United Therapeutics by 495.4% during the 2nd quarter. AXQ Capital LP now owns 3,888 shares of the biotechnology company’s stock worth $1,117,000 after acquiring an additional 3,235 shares in the last quarter. AE Wealth Management LLC grew its holdings in United Therapeutics by 396.3% during the 3rd quarter. AE Wealth Management LLC now owns 4,288 shares of the biotechnology company’s stock worth $1,798,000 after acquiring an additional 3,424 shares in the last quarter. Great Lakes Advisors LLC increased its position in shares of United Therapeutics by 194.7% in the 3rd quarter. Great Lakes Advisors LLC now owns 4,503 shares of the biotechnology company’s stock worth $1,888,000 after purchasing an additional 2,975 shares during the last quarter. Finally, Optimize Financial Inc acquired a new stake in shares of United Therapeutics in the 3rd quarter valued at about $444,000. Institutional investors and hedge funds own 94.08% of the company’s stock.

Analysts Set New Price Targets

Several analysts have issued reports on UTHR shares. Royal Bank Of Canada upped their price objective on United Therapeutics from $569.00 to $587.00 and gave the company an “outperform” rating in a research note on Thursday, October 30th. UBS Group raised their price target on shares of United Therapeutics from $600.00 to $645.00 and gave the stock a “buy” rating in a research report on Tuesday, January 6th. HC Wainwright raised their price target on United Therapeutics from $500.00 to $525.00 and gave the stock a “buy” rating in a report on Thursday, October 30th. Wells Fargo & Company increased their target price on United Therapeutics from $414.00 to $423.00 and gave the stock an “equal weight” rating in a research report on Thursday, October 30th. Finally, Jefferies Financial Group reiterated a “buy” rating and issued a $575.00 target price on shares of United Therapeutics in a research note on Wednesday, November 19th. Eight equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $509.50.

Insider Transactions at United Therapeutics

In other United Therapeutics news, COO Michael Benkowitz sold 22,500 shares of the business’s stock in a transaction dated Monday, November 17th. The shares were sold at an average price of $470.43, for a total value of $10,584,675.00. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Insiders sold 517,214 shares of company stock worth $249,206,113 over the last quarter. 10.30% of the stock is owned by insiders.

United Therapeutics Stock Performance

Shares of NASDAQ UTHR opened at $473.20 on Wednesday. United Therapeutics Corporation has a 1 year low of $266.98 and a 1 year high of $519.99. The stock has a fifty day moving average price of $486.59 and a two-hundred day moving average price of $430.69. The firm has a market cap of $20.38 billion, a P/E ratio of 17.93, a PEG ratio of 2.52 and a beta of 0.85.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.